help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Park, J.-W.
Right arrow Articles by Clark, O. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Park, J.-W.
Right arrow Articles by Clark, O. H.
The Journal of Clinical Endocrinology & Metabolism Vol. 88, No. 7 3346-3353
Copyright © 2003 by The Endocrine Society

The Heat Shock Protein 90-Binding Geldanamycin Inhibits Cancer Cell Proliferation, Down-Regulates Oncoproteins, and Inhibits Epidermal Growth Factor-Induced Invasion in Thyroid Cancer Cell Lines

Jin-Woo Park, Michael W. Yeh, Mariwil G. Wong, Margaret Lobo, William C. Hyun, Quan-Yang Duh and Orlo H. Clark

Department of Surgery, University of California, Mount Zion Medical Center (J.-W.P., M.W.Y., M.G.W., M.L., O.H.C.), San Francisco, California 94143-1674; University of California Comprehensive Cancer Center (W.C.H.), San Francisco, California 94115; and Surgical Services, Veterans Affairs Medical Center (Q.H.C.), San Francisco, California 94121

Address all correspondence and requests for reprints to: Orlo H. Clark, M.D., University of California/Mount Zion Medical Center (Surgery), 1600 Divisadero Street, San Francisco, California 94115. E-mail: clarko{at}surgery.ucsf.edu.

Heat shock protein 90 (HSP90) serves as a chaperone protein and plays a critical role in tumor cell growth and/or survival. Geldanamycin, a specific inhibitor of HSP90, is cytotoxic to several human cancer cell lines, but its effect in thyroid cancer is unknown. We, therefore, investigated the effect of geldanamycin on cell proliferation, oncoprotein expression, and invasion in human thyroid cancer cell lines. We used six thyroid cancer cell lines: TPC-1 (papillary), FTC-133, FTC-236, FTC-238 (follicular), XTC-1 (Hürthle cell), and ARO (anaplastic). We used the dimethyl-thiazol-diphenyltetrazolium bromide assay, a clonogenic assay, an apoptotic assay, and a Matrigel invasion assay. We evaluated oncoprotein expression using Western blots and flow cytometry. After 6 d of treatment with 50 nM geldanamycin, the percent inhibition of growth was 29.4% in TPC-1, 97.5% in FTC-133, 96.7% in FTC-236, 10.8% in FTC-238, 70.9% in XTC-1, and 45.5% in ARO cell lines. In the FTC-133 cell line, geldanamycin treatment decreased clonogenicity by 21% at a concentration of 50 nM; geldanamycin induced apoptosis and down-regulated c-Raf-1, mutant p53, and epidermal growth factor (EGF) receptor expression; geldanamycin inhibited EGF-stimulated invasion. In conclusion, geldanamycin inhibited cancer cell proliferation, down-regulated oncoproteins, and inhibited EGF-induced invasion in thyroid cancer cell lines.

Abbreviations: DTC, Differentiated thyroid cancer; EGF, epidermal growth factor; EGFR, EGF receptor; FCS, fetal calf serum; FITC, fluorescein isothiocyanate; FTC, follicular thyroid cancer; GRP94, glucose-regulated protein 94; HSP90, heat shock protein 90; IgG, immunoglobulin G; MTT, dimethyl-thiazol-diphenyltetrazolium bromide; PI, propidium iodide; RB, retinoblastoma gene product.




This article has been cited by other articles:


Home page
Anticancer ResHome page
F. KOGA, K. KIHARA, and L. NECKERS
Inhibition of Cancer Invasion and Metastasis by Targeting the Molecular Chaperone Heat-shock Protein 90
Anticancer Res, March 1, 2009; 29(3): 797 - 807.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
C. Moser, S. A. Lang, S. Kainz, A. Gaumann, S. Fichtner-Feigl, G. E. Koehl, H. J. Schlitt, E. K. Geissler, and O. Stoeltzing
Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo
Mol. Cancer Ther., November 1, 2007; 6(11): 2868 - 2878.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
A. Chrisoulidou, G. Kaltsas, I. Ilias, and A. B Grossman
The diagnosis and management of malignant phaeochromocytoma and paraganglioma
Endocr. Relat. Cancer, September 1, 2007; 14(3): 569 - 585.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
A S Rao, N Kremenevskaja, J Resch, and G Brabant
Lithium stimulates proliferation in cultured thyrocytes by activating Wnt/{beta}-catenin signalling
Eur. J. Endocrinol., December 1, 2005; 153(6): 929 - 938.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. S. Rao, P. E. Goretzki, J. Kohrle, and G. Brabant
Letter re: Id1 Gene Expression in Hyperplastic and Neoplastic Thyroid Tissues
J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5906 - 5906.
[Full Text] [PDF]


Home page
Neuro Oncol DukeHome page
M. W. Graner and D. D. Bigner
Chaperone proteins and brain tumors: Potential targets and possible therapeutics
Neuro-oncol, July 1, 2005; 7(3): 260 - 278.
[Abstract] [PDF]


Home page
Clin. Cancer Res.Home page
X. Yin, H. Zhang, F. Burrows, L. Zhang, and C. G. Shores
Potent Activity of a Novel Dimeric Heat Shock Protein 90 Inhibitor against Head and Neck Squamous Cell Carcinoma In vitro and In vivo
Clin. Cancer Res., May 15, 2005; 11(10): 3889 - 3896.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Hoffmann, L. C. Hofbauer, V. Scharrenbach, A. Wunderlich, I. Hassan, S. Lingelbach, and A. Zielke
Thyrotropin (TSH)-Induced Production of Vascular Endothelial Growth Factor in Thyroid Cancer Cells in Vitro: Evaluation of TSH Signal Transduction and of Angiogenesis-Stimulating Growth Factors
J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6139 - 6145.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. K. Marsee, A. Venkateswaran, H. Tao, D. Vadysirisack, Z. Zhang, D. D. Vandre, and S. M. Jhiang
Inhibition of Heat Shock Protein 90, a Novel RET/PTC1-associated Protein, Increases Radioiodide Accumulation in Thyroid Cells
J. Biol. Chem., October 15, 2004; 279(42): 43990 - 43997.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Braga-Basaria, E. Hardy, R. Gottfried, K. D. Burman, M. Saji, and M. D. Ringel
17-Allylamino-17-Demethoxygeldanamycin Activity against Thyroid Cancer Cell Lines Correlates with Heat Shock Protein 90 Levels
J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2982 - 2988.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
K. D. Burman
A New Paradigm in the Treatment of Carcinoma: Specific Molecular Targeting
Endocrinology, March 1, 2004; 145(3): 1027 - 1030.
[Full Text] [PDF]


Home page
Cancer Res.Home page
K. S. Bisht, C. M. Bradbury, D. Mattson, A. Kaushal, A. Sowers, S. Markovina, K. L. Ortiz, L. K. Sieck, J. S. Isaacs, M. W. Brechbiel, et al.
Geldanamycin and 17-Allylamino-17-demethoxygeldanamycin Potentiate the in Vitro and in Vivo Radiation Response of Cervical Tumor Cells via the Heat Shock Protein 90-Mediated Intracellular Signaling and Cytotoxicity
Cancer Res., December 15, 2003; 63(24): 8984 - 8995.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2003 by The Endocrine Society